eli lilly tirzepatide patient assistance program Lilly, Maker of Mounjaro and Zepbound, Wades Into Telehealth What is Lilly Cares |

Ozempic is a GLP-1 receptor agonist licensed for type 2 diabetes, not weight management in the UK

THE BOTTOM LINE Different Mechanisms: Ozempic (semaglutide) is a GLP-1 receptor agonist , while Mounjaro (tirzepatide) is a dual-agonist that targets both GLP-1 and GIP receptors

Always consult your physician before starting any new treatment

The renoprotective effect of GLP-1RA can be achieved by reducing urinary protein levels and the glomerular filtration rate (66, 67)

Oestrogen levels affect womens hair growth and fat cells produce oestrogen, meaning weight loss can affect women differently

The appetite suppression becomes more pronounced as the dose increases